Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.3152W HIGH $6.21
Volume
1.09 M
Value Traded
5.47 M
Short % Float
4.38%
Days to Cover
3.1
+1.95%Week
+4.17%1 Month
+21.15%3 Month
+18.28%6 Month
-80.05%5 Year
-80.05%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
714.91 M
EPS (TTM)
-0.62
P/E Ratio
-
Ent. Value
452.90 M
Total Shares
129.97 M
Float Shares
118.96 M
Insiders
8.48%
Institutions
63.04%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CTKB Catalyst Timeline
Dated clinical, regulatory and corporate events for Cytek Biosciences, Inc.
Past FDA Catalysts and PDUFA Decisions
How CTKB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Cytek Biosciences, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CTKB program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McCombe William D.Officer (Chief Financial Officer) | Option | 6,320 117,497 held | $0.00 | 08/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CTKB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.6 % (-40 %) | 45.69 M | 6.81 M |
CTKB Institutional Ownership Trends
CTKB Short Interest
Shares sold short, counted twice a month.
4.38%
Short % of Float
of tradable shares sold short
5.2M
Shares Sold Short
-0.5% vs prior count
3.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CTKB ranks across every disease it competes in
Competitive Position is a premium feature
See how CTKB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCTKB News
CTKB▲ +3%today
Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Cytek Biosciences will announce its financial results for Q3 2026 on November 4, 2026. A conference call will follow at 1:30 p.m. PT to discuss the results and future outlook. The company specializes in advanced cell analysis tools using its Full Spectrum Profiling technology.
Read more →CTKBCytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
Cytek Biosciences has launched a new Cloud Analysis tool as part of its Cytek Cloud digital ecosystem, enhancing its flow cytometry capabilities. This tool allows seamless integration from data acquisition to analysis, improving workflow efficiency for researchers. The platform, which has over 28,000 users, now offers three subscription tiers to cater to different research needs.
Read more →CTKBSysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
Sysmex Europe SE and Cytek Biosciences have announced a strategic collaboration to enhance clinical flow cytometry across Europe. This partnership aims to improve laboratory workflows by integrating Sysmex's established technologies with Cytek's advanced spectral flow cytometry solutions. The collaboration is designed to meet the increasing demand for efficient and standardized testing in clinical laboratories.
Read more →CTKBCytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
Cytek Biosciences will showcase its advanced spectral flow cytometry solutions at the ESCCA 2026 Conference and ICCS 2026. The company aims to demonstrate how its Full Spectrum Profiling technology can improve laboratory efficiency and data quality. Cytek's participation includes presentations and workshops aimed at enhancing the understanding of spectral cytometry in clinical applications.
Read more →CTKBCytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences, Inc. (Nasdaq: CTKB) has announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Key executives, including CEO Wenbin Jiang and CFO William McCombe, will be involved in discussions and meetings. Interested parties can access webcasts for these events through the company’s website.
Read more →CTKB▼ -7.7%on this news
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
Cytek Biosciences won a jury verdict in a patent infringement case, with the jury favoring Cytek on three of four claims. The company plans to contest the remaining finding of infringement and the associated damages of $56 million. Despite this, Cytek's product offerings remain unaffected, and the company is committed to its innovative Full Spectrum Profiling technology.
Read more →CTKBCytek Biosciences Reports Second Quarter 2026 Financial Results
Cytek Biosciences reported a 6% increase in total revenue for Q2 2026, reaching $48.1 million. The company launched new products, including the Cytek Borealis flow cytometer, and saw growth in recurring revenue. However, operating expenses rose significantly, leading to a net loss of $12.2 million. The company updated its full-year revenue guidance to between $207 million and $212 million.
Read more →CTKBCytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Cytek Biosciences, Inc. will announce its second quarter 2026 financial results on August 5, 2026. A conference call will follow to discuss the results and the company's business outlook. The event underscores Cytek's commitment to transparency and investor engagement.
Read more →CTKBCytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
Cytek Biosciences has opened a new innovation center in Bellevue, Washington, relocating from Seattle. The facility is designed to enhance research and development while promoting collaboration and customer engagement. It includes R&D laboratories, training areas, and employee-focused amenities. This move reflects Cytek's commitment to advancing scientific discovery and innovation.
Read more →CTKBCytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference
Cytek Biosciences, Inc. announced its participation in the Singular Research’s Las Vegas Invitational Conference from June 14-16, 2026. The company's management will present on June 15 at 11:00 a.m. PT. Interested parties can access the presentation via a live and archived webcast on the company's investor website.
Read more →CTKBCytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Cytek Biosciences will showcase its new 7-laser Cytek Borealis full spectrum flow cytometer and enhanced Cytek Aurora Evo system at CYTO 2026. These innovations aim to improve flexibility, scalability, and efficiency in cell analysis. The Borealis system features advanced optical capabilities and integrated imaging, while the Aurora Evo updates focus on automation to support biopharma research.
Read more →CTKBCytek Biosciences Reports First Quarter 2026 Financial Results
Cytek Biosciences reported a 6% increase in total revenue for Q1 2026, reaching $44.1 million. Service revenue grew by 15%, contributing to a rise in recurring revenue to 35% of total revenue. However, the company experienced an increase in operating expenses and a higher net loss compared to the previous year. Cytek reaffirms its revenue guidance for 2026.
Read more →CTKB▼ -8.4%on this news
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Cytek Biosciences, Inc. will announce its financial results for Q1 2026 on May 7, 2026. A conference call will follow to discuss the results and future outlook. The company specializes in advanced cell analysis solutions, utilizing its patented Full Spectrum Profiling technology. Investors can access the webcast via the company's website.
Read more →CTKBCytek Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences has completed its first year of operations at its 8,500-square-foot facility in Singapore, marking a significant milestone in its expansion efforts in the Asia-Pacific region. The facility has improved Cytek's manufacturing capacity and regional service capabilities while also enhancing global supply chain resilience. Driven by increasing demand for cellular analysis solutions, the expansion is expected to support sustained business growth in this key market. Cytek's commitment to local partnerships aims to drive innovation and talent development in Singapore's MedTech ecosystem.
Read more →CTKBCytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
Cytek Biosciences reported its fourth quarter and full year 2025 financial results, highlighting an 8% revenue increase in Q4, driven by strong instrument sales. However, the company also faced a net loss of $44.1 million in Q4 2025, a significant decline from profits in the previous year. Operating expenses surged by 25.5%, contributing to a full year net loss of $66.5 million. Looking ahead, Cytek projects a revenue increase for 2026, targeting between $205 million to $212 million.
Read more →CTKBCytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
Cytek Biosciences, Inc. (Nasdaq: CTKB) has announced its participation in the TD Cowen 46th Annual Health Care Conference, taking place in Boston, MA. The management team will engage in a hybrid presentation and fireside chat on March 4th, aimed at showcasing the company's advanced cell analysis solutions and technology. Interested attendees can access the event via a live and archived webcast through the company's investor relations website. Cytek is known for its innovative Full Spectrum Profiling technology, which enhances cell analysis capabilities.
Read more →CTKBCytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Cytek Biosciences announced it will report its financial results for the fourth quarter and full year of 2025 on February 26, 2026. The company will hold a webcast conference call at 1:30 PM PT to discuss these results, along with business developments and future outlook. Cytek is known for its advanced cell analysis technologies, operating with a strong emphasis on high-resolution and high-sensitivity analysis through its proprietary Full Spectrum Profiling technology. The event will provide insights into the company's performance and strategic direction.
Read more →CTKB▲ +6.4%on this news
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Cytek Biosciences, Inc. announced preliminary unaudited revenue results for 2025, expecting total revenue to reach approximately $201 million. The fourth quarter revenue is anticipated to be about $62 million, marking an 8% increase from the previous year. Positive trends include growth in services, reagents, and a return to positive revenue growth in EMEA, which the CEO regards as a sign of sustainable potential. However, the results are preliminary and subject to revision upon audit.
Read more →CTKBTIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026
Cytek Biosciences has been named one of America's Growth Leaders of 2026 by TIME, highlighting its exceptional growth and financial stability over the past five years. The recognition underscores Cytek's commitment to innovation in high-parameter cell analysis solutions, which are crucial for advancing research in health and science. CEO Wenbin Jiang emphasized the company's mission to make cell analysis accessible and effective for all laboratories.
Read more →CTKBCytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year
Cytek Biosciences' Muse Micro cell analyzer has been awarded Drug Discovery Solution of the Year at the 2025 BioTech Breakthrough Awards. This recognition emphasizes the system's affordability and ease of use, making sophisticated cell analysis accessible to smaller laboratories. The Muse Micro system builds on the legacy of the original Guava Muse system, enhancing flow cytometry capabilities.
Read more →About Cytek Biosciences, Inc.
Headquarters47215 LAKEVIEW BOULEVARD, FREMONT, CA, 94538
BIOPHARMAWATCH ELITE PLUS
Trade the next CTKB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime